ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0517 • ACR Convergence 2023

    Which ASDAS Cut-Off Corresponds Best to Treatment Intensification in Patients with Axial Spondyloarthritis in Daily Practice?

    Casper Webers1, Rabab Nezam El-Din1, Marin Been1, Harald Vonkeman2 and Astrid van Tubergen1, 1Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, 2Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands

    Background/Purpose: In patients with axial spondyloarthritis (axSpA) and high disease activity (typically defined as Ankylosing Spondylitis Disease Activity Score [ASDAS]≥2.1), it is recommended to adapt…
  • Abstract Number: 0498 • ACR Convergence 2023

    Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)

    Arad Dotan1, Niv Ben-Shabbat1, Abdulla watad2, Dennis McGonagle3 and Howard AMITAL2, 1Department of Medicine 'B'. Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, 2Sheba Medical Center, Ramat Gan, Israel, 3Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Major adverse cardiovascular events (MACE) are known comorbidities and consequences of psoriasis (PsO) and psoriasis arthritis (PsA). Previous studies underlined the potential of immunomodulatory…
  • Abstract Number: 0540 • ACR Convergence 2023

    The Impact of Baseline BMI and Physical Activity on Upadacitinib Treatment Response: A Post Hoc Analysis of Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Study

    Angela Crowley1, Lori Siegel1, Pendleton Wickersham2, Heather Jones3, Dan Webster4, Anna Shmagel5, Ana Biljan6, Uta Kiltz7 and Philip Helliwell8, 1Illinois Bone and Joint Institute, Gurnee and Hinsdale, IL, 2Methodist Hospital, Baptist Medical Center and CHRISTUS Santa Rosa Hospital - Westover Hills, San Antonio, TX, 3AbbVie, Inc., Mettawa, IL, 4AbbVie, Inc., Libertyville, IL, 5AbbVie, Inc., Long Grove, IL, 6AbbVie, Inc., Buffalo Grove, IL, 7Rheumazentrum Ruhrgebiet, Herne, Germany, 8University of Leeds, Leeds, United Kingdom

    Background/Purpose: In patients (pts) with AS, higher BMI has been linked to higher disease activity1. However, given that BMI can be a poor indicator of…
  • Abstract Number: 0496 • ACR Convergence 2023

    Higher Values of Atherogenic Index of Plasma Are Correlated with Increased Cardiovascular Risk in Patients with Psoriatic Arthritis

    Valeria Gonzalez-Gonzalez1, Iris Colunga2, Dionicio A. Galarza-Delgado2, José Ramón Azpiri-López2, Rosa Arvizu-Rivera3, Jesus Alberto Cardenas-De la Garza4, Victor Beltran5 and Angel Arias Peralta6, 1Universidad Autónoma de Nuevo León, Monterrey, Mexico, 2Hospital Universitario UANL, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, 4Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, 5Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, 6Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico

    Background/Purpose: The atherogenic index of plasma (AIP) is a predictor of atherosclerosis and coronary heart disease. In patients with systemic lupus erythematosus and rheumatoid arthritis,…
  • Abstract Number: 0484 • ACR Convergence 2023

    Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study

    Lihi Eder1, Vinod Chandran2, Cheryl Rosen3, Richard J. Cook4 and Dafna Gladman5, 1Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, 3Division of Dermatology, Toronto Western Hospital, Toronto, ON, Canada, 4Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Simple and accessible biomarkers that predict the development of psoriatic arthritis (PsA) among psoriasis patients are critically needed to improve early detection of high-risk…
  • Abstract Number: 0510 • ACR Convergence 2023

    Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies

    Philip J. Mease1, Maxime Dougados2, Maureen Dubreuil3, Marina Nighat Magrey4, Helena Marzo-Ortega5, Martin Rudwaleit6, Christine de la Loge7, Carmen Fleurinck8, Ute Massow9, Vanessa Taieb10 and Atul Deodhar11, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 2Department of Rheumatology, Hôpital Cochin, University of Paris Cité, Paris, France, 3Department of Rheumatology, Boston University School of Medicine, Milton, MA, 4Case Western Reserve University, University Hospitals, Cleveland, OH, 5NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 6University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Oosterzele, Belgium, 9UCB Pharma, Monheim am Rhein, Germany, 10UCB Pharma, Colombes, France, 11Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 studies BE MOBILE 1 and…
  • Abstract Number: 0508 • ACR Convergence 2023

    Assessment of Pain Outcomes in a Phase 2 Trial of a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active PsA

    Philip J. Mease1, Lihi Eder2, Alexis R Ogdie3, Atul Deodhar4, Subhashis Banerjee5, Miroslawa Nowak5, Jiyoon Choi6, Thomas Lehman7 and Vibeke Strand8, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 2Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 3University of Pennsylvania, Philadelphia, PA, 4Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, 5Bristol Myers Squibb, Princeton, NJ, 6Bristol Myers Squibb, Lawrenceville, NJ, 7Bristol Myers Squibb, Philadelphia, PA, 8Stanford University, Palo Alto, CA

    Background/Purpose: Pain is commonly cited by patients with PsA as affecting their daily activities and quality of life and may differ by sex1. In addition…
  • Abstract Number: 0561 • ACR Convergence 2023

    Frequency of Anti-Ro Antibodies in Systemic Lupus Erythematosus Patients: Insights from Multicenter and National Registry

    Lucia Margarita Mendoza Martinez1, Joan Manuel Dapeña1, Juan Manuel Bande1, Maria Alejandra Medina1, Silvia Papasidero1, José caracciolo1, Rosana Quintana2, Lucila Garcia2, Carla Andrea Gobbi2, Sandy Sapag Durán2, Alberto Spindler2, Analia Patricia Alvarez2, Cecilia Pisoni2, Catalina Gomez2, Raúl Hector Paniego2, María Julia Santa cruz2, Luciana Gonzalez Lucero2, Rodrigo Aguila Maldonado2, Sergio Gordon2, Julia Romero2, Gretel Rausch2, Alberto Allievi2, Alberto Omar Orden2, johana zacariaz hereter3, Roberto Baéz2, Andrea Vanesa González2, Juan Manuel Vandale2, Mario Alberto Goñi2, Victor Caputo4, María Silvia Larroudé2, Graciela Gómez2, Josefina Marin2, Victoria Collado2, Gazzoni María Victoria2, Marcos David Zelaya2, Mónica Sacnún2, Romina Rojas Tessel2, Maira Alejandra Arias Saavedra2, Maximiliano Machado Escobar2, Pablo Astesana2, Ursula Vanesa Paris2, Bernando A. Pons-Estel2 and Mercedes García5, 1Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, 2Study Group of the Argentine Society of Rheumatology for Systemic Lupus Erythematosus, Buenos Aires, Argentina, 3Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Hospital Militar Central, Buenos Aires, Argentina, 5Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina

    Background/Purpose: Anti-Ro antibodies can be detected in 40% of patients with systemic lupus erythematosus (SLE) and have been associated with various clinical manifestations of the…
  • Abstract Number: 0560 • ACR Convergence 2023

    Genetic Determinants of Lupus Nephritis and Kidney Function in Systemic Lupus Erythematosus

    Magdalena Riedl Khursigara1, Nicholas Gold2, Thai-Son Tang3, Daniela Dominguez2, Marisa Klein-Gitelman4, Dafna Gladman5, Daniel Goldman6, Elizabeth Harvey2, Mariko Ishimori7, Caroline Jefferies7, Diane L. Kamen8, Sylvia Kamphuis9, Andrea Knight2, Chia-Chi Lee7, Deborah Levy2, Damien Noone2, Karen Onel10, Christine Peschken11, Michelle Petri6, Janet Pope12, Eleanor Pullenayegum2, Earl Silverman13, Zahi Touma1, Murray Urowitz14, Daniel Wallace7, Joan Wither15 and Linda Hiraki2, 1University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3University of Toronto, Mississauga, ON, Canada, 4Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 5Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 6Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 7Cedars-Sinai Medical Center, Los Angeles, CA, 8Medical University of South Carolina, Charleston, SC, 9Sophia Children’s Hospital, Rotterdam, Netherlands, 10Hospital for Special Surgery, New York, NY, 11University of Manitoba, Winnipeg, MB, Canada, 12University of Western Ontario, London, ON, Canada, 13Silverman, Toronto, ON, Canada, 14Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, 15University Health Network, Toronto, ON, Canada

    Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestation of SLE. Risk factors for lupus nephritis and renal function decline are…
  • Abstract Number: 0549 • ACR Convergence 2023

    Development of Customized Digital Cognitive Assessment Battery: A Pilot Use Case in SLE Patients

    Priyanka Srivastava1 and Liza Rajasekhar2, 1International Institute of Information Technology, Hyderabad, India, 2Nizam's Institute of Medical Sciences, Madhapur, India

    Background/Purpose: Reported prevalence of cognitive dysfunction (CD) in SLE varies from 3%-88%1.Variability may be due to use of tools insensitive to population characteristics like literacy,…
  • Abstract Number: 0532 • ACR Convergence 2023

    Factors Associated with Cause-specific Discontinuation of Long-term Anti-tumor Necrosis Factor Agent Use in Patients with Ankylosing Spondylitis

    bora nam1, Nayeon Choi2, Bon San Koo3, Jiyeong Kim2, Ji-Hui Shin1, Seunghun lee4, kyung bin Joo4 and Tae-Hwan Kim1, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea, 3Inje University Seoul Paik Hospital, Seoul, South Korea, 4Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: Anti-tumor necrosis factor (TNF) agents have proven to be effective in treating Ankylosing spondylitis (AS). However, a significant number of patients discontinue or switch…
  • Abstract Number: 0450 • ACR Convergence 2023

    Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting

    Martinus Van de Laar1, Martijn Oude Voshaar1, Peter ten Klooster1, Danyta Tedjo2 and celine van de laar3, 1University of Twente, Hengelo (OV), Netherlands, 2TiH @ University of Twente, Hengelo (OV), Netherlands, 3Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands

    Background/Purpose: The EULAR guidelines for Rheumatoid Arthritis (RA) patients advise to use a strategy aiming at a predefined target of disease activity (T2T). If this…
  • Abstract Number: 0569 • ACR Convergence 2023

    Serum S100A8 and S100A9 Are Useful Biomarker Indicated IFN Associated Organ Involvements in Systemic Lupus Erythematosus

    Risa Wakiya1, Hiromi Shimada1, Shusaku Nakashima1, Taichi Miyagi2, Yusuke Ushio3, Koichi Sugihara4, Mao Mizusaki1, Rina Mino5, Kanako Chujo6, Ryoko Kagawa3, Hayamasa Yamaguchi3, Tomohiro Kameda1 and Hiroaki Dobashi1, 1Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 2Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, 3Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, 4Kagawa University, Miki-cho, Kita-gun, Japan, 5Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 6Kagawa University, Miki, Kita District, Kagawa, Japan

    Background/Purpose: S100, a damage-related molecular pattern factor, was reported to be a biomarker associated with disease activity in SLE. Additional hydroxychloroquine, which could regulate IFN…
  • Abstract Number: 0531 • ACR Convergence 2023

    Effects of Anti-tumor Necrosis Factor Treatment on Lipid Profiles in Patients with Ankylosing Spondylitis

    Inbeom Kwon1, bora nam2, Nayeon Choi3, Ji-Hui Shin2, Seunghun lee4 and Tae-Hwan Kim2, 1Department of Medicine, Hanyang University College of Medicine, Seoul, South Korea, 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea, 4Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: To investigate the effects of anti-tumor necrosis factor (anti-TNF) treatment on lipid profiles and identify risk factors for elevated total cholesterol (TC) after the…
  • Abstract Number: 0571 • ACR Convergence 2023

    A Polygenic Risk Score for Systemic Lupus Erythematosus (SLE) Discriminates Between Patients with Lupus and Individuals Without Lupus and a Positive Antinuclear Antibody Test

    Gul Karakoc1, Ge Liu1, Jacy Zanussi2, Cecilia Chung2, Jorge Gamboa1, Jonathan Mosley1, Nancy Cox1, C. Michael Stein1 and Vivian Kawai1, 1Vanderbilt University Medical Center, Nashville, TN, 2University of Miami, Miami, FL

    Background/Purpose: A positive ANA (ANA-POS) test is present in almost all patients with SLE and is also frequently present in other autoimmune (AI) diseases and…
  • « Previous Page
  • 1
  • …
  • 304
  • 305
  • 306
  • 307
  • 308
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology